Neurocrine Biosciences (NBIX) Preferred Stock Liabilities (2024)
Neurocrine Biosciences (NBIX) posted Preferred Stock Liabilities of $136.2 million for Q1 2024.
Neurocrine Biosciences (NBIX) Preferred Stock Liabilities (2024) Analysis & Trends
Neurocrine Biosciences' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $136.2 million for Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 136.20 Mn |